Cheryl Thompson
Professor and Associate Director for Population Sciences, Penn State Cancer Institute
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Introduction Women undergoing breast cancer (BC) treatment often face side effects that impact their quality of life and adherence. Biomarker tests to predict side effects could improve treatment options and adherence. This study assessed the prevalence of common side effects and women’s preferences for biomarker testing. Methods Data from surveys of patients with BC at University Hospitals Cleveland Medical Center (UHCMC; N = 586) and Penn State Cancer Institute (PSCI; N = 562) were analyzed using descriptive statistics, chi-square, and Mann–Whitney U . Results In the UHCMC and PSCI cohorts, 53.2% and 60.2% of the women prescribed endocrine therapy experienced joint and musculoskeletal pain (JMSP), respectively, with approximately one third discontinuing or changing treatment for BC. JMSP was associated with a higher mean body mass index (BMI). Over half of the women experienced hot flashes which were associated with younger age and Black race. Of the women receiving chemotherapy, nearly two thirds experienced neuropathy. Approximately one quarter of the respondents reported lymphedema, which as associated with a higher mean BMI, chemotherapy, and Black race. Quality of life was negatively impacted by side effects. Most women who experienced a side effect were more likely to prefer having a predictive test with the exception of women who experienced taxane-induced peripheral neuropathy. Conclusion Side effects from BC treatment negatively affect quality of life and could be mitigated if their likelihood was known. Since the majority of BC patients view predictive biomarker testing favorably, future work focusing on treatment side effects is crucial to improve adherence, particularly to endocrine therapy.
Year:
2025
Purpose: Patients with stage II and resected stage III melanomas have variable clinical outcomes, providing evidence of underlying biological differences in tumors and/or the patients themselves, beyond stage. The approval of adjuvant immunotherapy for stage IIB/C and resected stage III/IV disease (and adjuvant targeted therapy for resected stage III disease) has created a pressing need to develop biomarkers to accurately distinguish patients at low risk versus high risk for recurrence and death from melanoma. miRNAs are promising biomarkers because of their stability in tissues and fluids and their demonstrated functional and prognostic roles in melanoma. We hypothesized that miRNA expression could be integrated into prognostic models that would classify 5-year survival outcomes more accurately than clinical factors alone. Experimental Design: Using a NanoString miRNA Expression Assay, we analyzed 715 primary melanomas from patients with stage II or stage III disease within the InterMEL consortium and examined associations between miRNA expression and melanoma-specific death. Results: When integrated into clinical prognostic models for 5-year melanoma-specific survival, miRNA signatures improved the area under the receiver operating characteristic curve for patients in stage II from 0.71 for a “clinical factors–only” model to 0.81 for a “clinical plus miRNA” model in an independent test set, an improvement of 0.10 with a 95% confidence interval (0.03–0.19). The improvement was more modest for patients in stage III who were included in the analysis. Conclusions: Incorporating miRNA expression in primary melanomas may enhance the accuracy of clinical prognostic models and potentially aid in the selection of patients with melanoma for adjuvant treatment and clinical trials.
Year:
2025
Breast cancer subtypes and their phenotypes parallel different stages of the mammary epithelial cell developmental hierarchy. Discovering mechanisms that control lineage identity could provide novel avenues for mitigating disease progression. Here we report that the transcriptional corepressor TLE3 is a guardian of luminal cell fate in breast cancer and operates independently of the estrogen receptor. In luminal breast cancer, TLE3 actively repressed the gene-expression signature associated with highly aggressive basal-like breast cancers (BLBC). Moreover, maintenance of the luminal lineage depended on the appropriate localization of TLE3 to its transcriptional targets, a process mediated by interactions with FOXA1. By repressing genes that drive BLBC phenotypes, including SOX9 and TGFβ2 , TLE3 prevented the acquisition of a hybrid epithelial–mesenchymal state and reduced metastatic capacity and aggressive cellular behaviors. These results establish TLE3 as an essential transcriptional repressor that sustains the more differentiated and less metastatic nature of luminal breast cancers. Approaches to induce TLE3 expression could promote the acquisition of less aggressive, more treatable disease states to extend patient survival. Significance: Transcriptional corepressor TLE3 actively suppresses SOX9 and TGFβ transcriptional programs to sustain the luminal lineage identity of breast cancer cells and to inhibit metastatic progression.
Year:
2025
Year:
2024
Collaborators (24)
Yuting Lu
New York University
Graham Mann
Professor
University of Sydney
Adam Reynolds
Research Assistant Professor
University of New Mexico
Shaofeng Yan
-
Yongzhao Shao
New York University Grossman School of Medicine
Christopher I. Amos
Associate Director for Population and Data Science
Baylor College of Medicine
Pauline Funchain
Stanford University
Marcus Bosenberg
Professor
Yale University
Steven Sizemore
Associate Professor
The Ohio State University Wexner Medical Center
Marianne Berwick
Professor
University of New Mexico
David Ollila
Professor of Surgery
University of North Carolina at Chapel Hill
Marc Ernstoff
Chief
National Institutes of Health
Anne E Cust
Deputy Director, The Daffodil Centre
University of Sydney
Ruth A Keri
Case Western Reserve University
David Polsky
Alfred W. Kopf, M.D. Professor of Dermatologic Oncology and Professor (Clinical) of Pathology (Academic)
NYU School of Medicine
Tim Lee
The University of British Columbia
Pei-Fen Kuan
Professor
Stony Brook University
Paul Googe
Professor and Laboratory Director
University of North Carolina at Chapel Hill
James Wilmott
Associate Professor
The University of Sydney Library
Iman Osman
NYU Langone Health
Eva Hernando
Professor
NYU Langone Medical Center
Sheri L. Holmen
Professor
University of Utah Health Sciences Center
Richard A. Scolyer
Faculty Member
University of Sydney
E. Nagore
Profesor Asociado
Universidad Católica de Valencia San Vicente Mártir Facultad de Medicina Facultad de Medicina y Odontología
Make your next move.
Prepare your application
Review drafts before you send them.